Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305760 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL27523612 | 0.83 | RAB9A (0.53) | ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL65904 | 0.81 | MEN1 (0.47) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL9984731 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL29226981 | 0.80 | MEN1 (0.46) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3633415 | 0.80 | ALDH1A1 (0.38) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| Bromide SCHEMBL4524176 | 0.80 | MEN1 (0.46) | ALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28051579 | 0.80 | MEN1 (0.46) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL28564497 | 0.79 | TDP1 (0.41) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1177836 | 0.78 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-10246486-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-RE47334-E1 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| CN-105829305-B | NRF2 regulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-30 | — | — | CN | disclosed |
| US-9873716-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873716-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2859009-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-2861604-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002024763-A1 | OLEFIN POLYMERISATION CATALYST | ATOFINA (FR) | 2002-03-28 | — | — | WO | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| EP-0265117-B1 | 2-SUBSTITUTED ALKYL CARBAPENEM ANTIBACTERIALS | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5021565-A | Novel 2-substituted alkyl carbapenem antibacterials | MERCK & CO., INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0265117-A1 | 2-substituted alkyl carbapenem antibacterials | MERCK & CO. INC. (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190737-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885MAPK1 2314/4885L3MBTL1 2766/4885 |
| US-10246486-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 1076/4885MAPK1 2314/4885L3MBTL1 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.